HK1220900A1 - 癌症的治療 - Google Patents

癌症的治療

Info

Publication number
HK1220900A1
HK1220900A1 HK16108998.7A HK16108998A HK1220900A1 HK 1220900 A1 HK1220900 A1 HK 1220900A1 HK 16108998 A HK16108998 A HK 16108998A HK 1220900 A1 HK1220900 A1 HK 1220900A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Application number
HK16108998.7A
Other languages
English (en)
Inventor
Rebecca Lambert Bent
Original Assignee
Ned Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ned Biosystems Inc filed Critical Ned Biosystems Inc
Publication of HK1220900A1 publication Critical patent/HK1220900A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16108998.7A 2013-04-12 2016-07-27 癌症的治療 HK1220900A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361811209P 2013-04-12 2013-04-12
PCT/US2014/033820 WO2014169221A2 (en) 2013-04-12 2014-04-11 Cancer therapy

Publications (1)

Publication Number Publication Date
HK1220900A1 true HK1220900A1 (zh) 2017-05-19

Family

ID=50771615

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108998.7A HK1220900A1 (zh) 2013-04-12 2016-07-27 癌症的治療

Country Status (10)

Country Link
US (3) US10195219B2 (zh)
EP (1) EP2983673A2 (zh)
JP (4) JP2016516781A (zh)
CN (3) CN112023054A (zh)
AU (3) AU2014250795B2 (zh)
BR (1) BR112015024537B1 (zh)
CA (1) CA2909349C (zh)
HK (1) HK1220900A1 (zh)
SG (2) SG11201509707QA (zh)
WO (1) WO2014169221A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516781A (ja) 2013-04-12 2016-06-09 ネッド バイオシステムズ， インコーポレイテッド 癌治療
CN112023053A (zh) * 2014-07-17 2020-12-04 益生菌股份公司 治疗对化疗有抗性的肿瘤的组合物及其应用
WO2016139625A1 (en) 2015-03-05 2016-09-09 Probiotical S.P.A. Compositions for use in the treatment of tumors resistant to chemotherapy
US20190321311A1 (en) * 2016-06-15 2019-10-24 Deutsches Krebsforschungszentrum Cancer Treatment by Simultaneous Targeting Energy Metabolism and Intracellular pH
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
US20190105340A1 (en) * 2017-10-05 2019-04-11 New York Genome Center, Inc. Methods and compositions for targeting vascular mimicry
WO2019207057A1 (en) * 2018-04-25 2019-10-31 Université Catholique de Louvain Combination of metformin and cyclophosphamide as an adjuvant in cancer immunotherapy
US20220111019A1 (en) * 2018-09-19 2022-04-14 Virginia Tech Intellectual Properties, Inc. Brca1 modulating compounds, formulations thereof, and uses thereof
CN109674990A (zh) * 2019-01-30 2019-04-26 中国人民解放军西部战区总医院 具有调节egfr作用的组合物及其制备方法
KR102347996B1 (ko) * 2020-03-02 2022-01-07 아주대학교산학협력단 메트포르민을 유효성분으로 포함하는 혈관신생 억제용 약학적 조성물
CN111419831B (zh) * 2020-04-08 2021-09-21 温州医科大学 二甲双胍靶向cox6b2在制备治疗胰腺癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
PT656786E (pt) 1992-05-19 2004-11-30 Novogen Res Pty Ltd Utilizacao de extractos do fitoestrogenio isoflavona de soja ou trevo
WO2001078783A2 (en) 2000-04-17 2001-10-25 Hauser, Inc. Compositions comprising natural agents for treatment of cancer
CA2760179A1 (en) * 2009-05-15 2010-11-18 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
CN102596192A (zh) * 2009-08-25 2012-07-18 哈佛大学校长及研究员协会 二甲双胍在癌症治疗和预防中的用途
JP6320756B2 (ja) 2010-12-06 2018-05-09 キュア キャンサー ワールドワイド エルエルシー 癌を治療するための化学および免疫療法を用いた癌細胞の代謝標的法
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
JP2016516781A (ja) 2013-04-12 2016-06-09 ネッド バイオシステムズ， インコーポレイテッド 癌治療

Also Published As

Publication number Publication date
AU2022202814A1 (en) 2022-05-19
CN112022853A (zh) 2020-12-04
JP6870046B2 (ja) 2021-05-12
US11083740B2 (en) 2021-08-10
US20160030454A1 (en) 2016-02-04
AU2014250795B2 (en) 2019-07-18
AU2019236645B2 (en) 2022-02-03
CA2909349C (en) 2023-01-03
JP2021001234A (ja) 2021-01-07
AU2019236645A1 (en) 2019-10-17
SG11201509707QA (en) 2015-12-30
EP2983673A2 (en) 2016-02-17
JP6757360B2 (ja) 2020-09-16
AU2014250795A1 (en) 2015-09-03
JP2018119013A (ja) 2018-08-02
JP2016516781A (ja) 2016-06-09
US20190175626A1 (en) 2019-06-13
CA2909349A1 (en) 2014-10-16
WO2014169221A2 (en) 2014-10-16
WO2014169221A3 (en) 2015-01-15
CN112023054A (zh) 2020-12-04
BR112015024537A2 (pt) 2017-07-18
AU2019236645B9 (en) 2022-06-02
CN105120876A (zh) 2015-12-02
US20220168324A1 (en) 2022-06-02
BR112015024537B1 (pt) 2022-09-06
US10195219B2 (en) 2019-02-05
BR112015024537A8 (pt) 2019-12-10
JP2019203034A (ja) 2019-11-28
SG10201913730RA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
IL245731A0 (en) Combined treatment for cancer
GB201322725D0 (en) Cancer therapy
EP2968343A4 (en) POLY THERAPY FOR TREATING CANCER
HK1220900A1 (zh) 癌症的治療
SG10201801965RA (en) Treatment of cancer with dihydropyrazino-pyrazines
SG11201507847UA (en) Cancer therapy
IL242017B (en) Cancer treatment with dihydopyrazino-pyrazines
EP3007756A4 (en) Catheter-assisted tumor treatment
GB201308440D0 (en) Therapeutic
ZA201507755B (en) Tumor-selective combination therapy
EP3044593A4 (en) Cancer therapy
GB201310755D0 (en) Therapy
HK1215195A1 (zh) 基於 分層的癌症治療
EP2961412A4 (en) CANCER THERAPY
HK1223547A1 (zh) 癌症治療方法
GB201403083D0 (en) Treatment of cancer
GB201318668D0 (en) Sonosensitive therapeutic
HK1232118A1 (zh) 癌症的治療
GB201307269D0 (en) Combination Therapy
GB201308039D0 (en) Photodynamic therapy
GB201518731D0 (en) Tumour Therapy
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
EP3013332A4 (en) Cancer treatment
GB201317213D0 (en) Cancer Therapy
GB201308365D0 (en) Tumour therapy